Findings from the ONTARGET/TRANSCEND trials revealed that the use of angiotensin-converting enzyme (ACE) inhibitors or ARBs contributed to the reduction of albuminuria and a decrease in cognitive decline among individuals with CKD (8). Here, ACE is linked to chronic kidney disease.